← Human Trials & Peer-Reviewed Studies
ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)
Plain-language guide to NCT06487585: phase 4 interventional trial of Angiotensin II, 100 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06487585
- Phase
- phase 4
- Status
- recruiting participants
- Start
- 2025-05-06
- Completion (planned or actual)
- 2026-01
- Participants
- 100 (estimated)
- Design
- na, open label (everyone knows who gets what), treatment
- Conditions studied
- Vasodilatory Hypotension During or After Cardiac Surgery
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
The trial (phase 4) is built around Angiotensin II.
The purpose of this research is to evaluate the use of Angiotensin II in patients with low blood pressure post-surgery.
Your information will be collected for 28 days post the procedure and initiation of the study drug to assess for safety events and complications.
It had 1 arm (groups): Study Drug Arm - Angiotensin II arm (other).
Angiotensin II.
The registry classes the interventions as drug.
Who Took Part
Enrollment: 100 planned participants were the target.
It was open to people of any sex aged from 18 years with no upper age limit.
Healthy volunteers could join, not only people with the condition.
Examples of who could join: Adult patients ≥ 18 years of age undergoing cardiac surgery requiring CPB. Patients must have clinical features of vasodilation as determined by a MAP \< 65 mmHg that is non-transient in the opinion of the treating physician. Patients must be adequately volume resuscitated in the opinion of the treating physician.
The full record lists 5 inclusion and 5 exclusion criteria; among the exclusions: patients on ecmo; patients with active endocarditis.
How the Study Was Run
Design: single-group and open-label.
Everyone knew when Angiotensin II was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.
Everyone received the same intervention, so there was no separate comparison group inside the trial.
It started in 2025-05-06 with completion listed for 2026-01.
It ran at 1 site in United States.
Its stated primary purpose is treatment.
What Was Measured
The main thing measured (primary outcome): Incidence of postoperative acute kidney injury, atrial fibrillation (time frame: 28 days).
It also tracked 7 secondary outcomes, for example Hours on Vasopressors, Total IVF, ICU LOS, Postoperative LOS, Any major STS complication and 30-day mortality.
What This Means in Plain Language
Put simply, this is a phase 4 trial of Angiotensin II in 100 people.
It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.